310 related articles for article (PubMed ID: 21232796)
1. Sudden acute leukemia transformation in a MDS patient with del(5q) in complete cytogenetic remission after lenalidomide.
Breccia M; Cannella L; Latagliata R; Nanni M; Santopietro M; Loglisci G; Ferretti A; Barzotti R; Oliva EN; Alimena G
Leuk Res; 2011 Jun; 35(6):e69-70. PubMed ID: 21232796
[No Abstract] [Full Text] [Related]
2. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.
Göhring G; Giagounidis A; Büsche G; Kreipe HH; Zimmermann M; Hellström-Lindberg E; Aul C; Schlegelberger B
Ann Hematol; 2010 Apr; 89(4):365-74. PubMed ID: 19855965
[TBL] [Abstract][Full Text] [Related]
3. Myelodysplastic syndromes with del(5q): indications and strategies for cytogenetic testing.
Haferlach C; Bacher U; Tiu R; Maciejewski JP; List A
Cancer Genet Cytogenet; 2008 Dec; 187(2):101-11. PubMed ID: 19027491
[TBL] [Abstract][Full Text] [Related]
4. Haematological and cytogenetic responses after only 7 days of Lenalidomide in a patient with myelodysplastic syndrome and chromosome 5q deletion.
Hadiji Mseddi S; Kallel F; Kassar O; Elloumi M; Jedidi I; Sennana H; Fenaux P
Leuk Res; 2011 Sep; 35(9):e175-6. PubMed ID: 21658768
[No Abstract] [Full Text] [Related]
5. Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes.
Heise C; Carter T; Schafer P; Chopra R
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1663-72. PubMed ID: 20942636
[TBL] [Abstract][Full Text] [Related]
6. Morphologic analysis in myelodysplastic syndromes with del(5q) treated with lenalidomide. A Japanese multiinstitutional study.
Matsuda A; Taniwaki M; Jinnai I; Harada H; Watanabe M; Suzuki K; Yanagita S; Suzuki T; Yoshida Y; Kimura A; Tsudo M; Tohyama K; Takatoku M; Ozawa K
Leuk Res; 2012 May; 36(5):575-80. PubMed ID: 22172461
[TBL] [Abstract][Full Text] [Related]
7. Lenalidomide--a transforming therapeutic agent in myelodysplastic syndromes.
List A
Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S302-4. PubMed ID: 19778857
[TBL] [Abstract][Full Text] [Related]
8. Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK2(V617F) positive, del(5)(q13q33) myelodysplastic syndrome.
Mesa RA; Tefferi A; Li CY; Steensma DP
Leukemia; 2006 Nov; 20(11):2063-4. PubMed ID: 16990762
[No Abstract] [Full Text] [Related]
9. A delayed yet durable response to very short lenalidomide therapy and unexpected clone redistribution in a case of myelodysplastic syndrome with del(5q) and del(20q).
Xu F; Li X; Chang C; He Q; Zhang Z; Zhang Q; Wu L
Leuk Res; 2009 Nov; 33(11):e199-202. PubMed ID: 19592091
[No Abstract] [Full Text] [Related]
10. Long-term transfusion independence in del(5q) MDS patients who discontinue lenalidomide.
Giagounidis AA; Kulasekararaj A; Germing U; Radkowski R; Haase S; Petersen P; Göhring G; Büsche G; Aul C; Mufti GJ; Platzbecker U
Leukemia; 2012 Apr; 26(4):855-8. PubMed ID: 21960245
[No Abstract] [Full Text] [Related]
11. The role of lenalidomide in the management of myelodysplasia with del 5q.
Kelaidi C; Eclache V; Fenaux P
Br J Haematol; 2008 Feb; 140(3):267-78. PubMed ID: 18217896
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of lenalidomide treatment and complete cytogenetic remission in a case of myelodysplastic syndrome with del(5q) and del(9q).
Xiong B; Liu X; Zou P; Fan L; Chen W; Li W; Liu L
Leuk Res; 2010 Jul; 34(7):e169-72. PubMed ID: 20122730
[No Abstract] [Full Text] [Related]
13. Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion.
Oliva EN; Cuzzola M; Nobile F; Ronco F; D'Errigo MG; Laganà C; Morabito F; Galimberti S; Cortelezzi A; Aloe Spiriti MA; Specchia G; Poloni A; Breccia M; Ghio R; Finelli C; Iacopino P; Alimena G; Latagliata R
Eur J Haematol; 2010 Sep; 85(3):231-5. PubMed ID: 20491881
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2V617F mutation.
Nomdedeu M; Maffioli M; Calvo X; Martínez-Trillos A; Baumann T; Díaz-Beyá M; Aguilar JL; Rozman M; Costa D; Esteve J; Cervantes F; Colomer D; Nomdedeu B
Leuk Res; 2011 Sep; 35(9):1276-8. PubMed ID: 21764129
[No Abstract] [Full Text] [Related]
15. Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup.
Giagounidis AA; Germing U; Strupp C; Hildebrandt B; Heinsch M; Aul C
Ann Hematol; 2005 Sep; 84(9):569-71. PubMed ID: 15891887
[TBL] [Abstract][Full Text] [Related]
16. Treatment of deletion 5q acute myeloid leukemia with lenalidomide.
Lancet JE; List AF; Moscinski LC
Leukemia; 2007 Mar; 21(3):586-8. PubMed ID: 17230228
[No Abstract] [Full Text] [Related]
17. Role of lenalidomide in the treatment of myelodysplastic syndromes.
Komrokji RS; List AF
Semin Oncol; 2011 Oct; 38(5):648-57. PubMed ID: 21943671
[TBL] [Abstract][Full Text] [Related]
18. Lenalidomide induces cell death in an MDS-derived cell line with deletion of chromosome 5q by inhibition of cytokinesis.
Matsuoka A; Tochigi A; Kishimoto M; Nakahara T; Kondo T; Tsujioka T; Tasaka T; Tohyama Y; Tohyama K
Leukemia; 2010 Apr; 24(4):748-55. PubMed ID: 20130600
[TBL] [Abstract][Full Text] [Related]
19. Lenalidomide for del(5q) and non-del(5q) myelodysplastic syndromes.
Giagounidis AA
Semin Hematol; 2012 Oct; 49(4):312-22. PubMed ID: 23079061
[TBL] [Abstract][Full Text] [Related]
20. Lenalidomide in del 5q MDS: responses and side effects revisited.
Tiu RV; Sekeres MA
Leuk Res; 2011 Nov; 35(11):1440-1. PubMed ID: 21764127
[No Abstract] [Full Text] [Related]
[Next] [New Search]
